News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

PolyMedix Inc. (PYMX.OB) Presents New Data on Its Defensin-Mimetic Antibiotics at 52nd Annual ICAAC



9/12/2012 10:04:03 AM

RADNOR, Pa., Sept. 11, 2012 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a biotechnology company focused on developing innovative approaches to transforming the treatment of infectious diseases, today announced that the Company presented data on its defensin-mimetic antimicrobial compounds at the 52nd Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, CA. The presentations included results of the first Phase 2 clinical study of PolyMedix's lead defensin-mimetic, brilacidin (PMX-30063), which showed high clinical response rates in patients with acute bacterial skin and skin structure infections (ABSSSI) caused by Staphylococcus aureus.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES